2:00PM – 9/30/2014: Oncology II – Next Gen Immunotherapeutics @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London
Reporter: Aviva Lev-Ari, PhD, RN
Real Time Media Conference Coverage – Business and Scientific Channels by: https://pharmaceuticalintelligence.com
Co-Chaired by:
- Esteban Pombo-Villar, COO, Oxford BioTherapeutics
– Immunotherapy origin was in fever management. Biological approach on T cells that modulate the response in Cancer and target therapies to enhance the T cells response, vaccines are the breakthrough.
– Patient selection and cost of therapy
– combination therapy
- Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
– Oncology
Stem cells
Immunotherapy – combination therapy small and large molecule
Combination in high interest in Oncology
– Patient selection
– What we anticipate for the Future
– University research, Pfizer agents in use
– Testing of combination and how to prioritize patients for treatment of combination of agents
Panelists:
- Daniel Teper, CEO, Immune Pharmaceuticals Inc. Hamza Suria, President and CEO, AnaptysBio, Inc.
Israeli company, drug in diagnostics in Phase II, HUJI development
Conjugate to target receptors on surface of cell in immunodiagnostics, over-expression of protein, one or two molecules delivered to the cells directly, which tumor had which type of protein over-expression
– clinical or scientific bench — two approach types for improvement in Clinical Trials.If the improvement is only few percent, no investment forward is given. Tumor reduction, survival, animal models do not provide conviction
- Dragan Cicic, COO and CMO, Actinium Pharmaceuticals
– alpha level product, use chemo therapy to over ride cancer . Targeting a residual disease, Toxicity potential for killing 1 kg of tumor burden. Antibody targeted for bone marrow, regulator did not allow to use a single agent if the patient is a candidate for Bone marrow transplant. Need for models and guidance
– benefit bestowed on the patient, 20% cure rate vs. 1% cure, second drug more expensive yet more cost effective
- Philippe Mauberna, CEO, Nanobiotix
– Nanoparticles, medical device, less toxic more efficient is the goal.
– Accessibility of treatment, payers, bring cure to Patient and sensibility to the environment
- Richard Goodfellow, CEO, Scancell Holdings plc
– only Cancer Vaccine, right combination of technology to develop T cells combination of technologies, re-engineering antibodies, DNA works better with injection – T cell ability found by combination of the three technologies CD-4 T cells
– Different approach to different cancers in different stages
– Stage III, combinations of inhibitors and vaccines, if two are combine, 85% survival in Animal, thus, combination is encouraging, later stage disease, how early in diagnosis, increasing tools for early detection, thus, treating patients in early stage been easier that in an advanced stage.
– How to convert cancer into a chronic disease. avoid recurrence. Melanoma, see cancer in early stage, remove by surgery, strategy will be applicable to Melanoma, check point lung, bladder, immunotherapy, vaccines allows much flexibility. Core treatment to cancer. Testing certain combination per patient, cost of treatment in consideration
– Affordable care. manufacturing cost is vast. drugs are expensive, great utility to most patients
- Keith Blundy, CEO, Cancer Research Technology
– Largest institute n the UK, TTA in Cancer, Small molecules, biotherapeutics,
– New agents combined with existing agents
– methods investing in modifying microphase, astroid platform, switching macrophages, T cells antibody feasible to launch immunotherapy ,mutipeptide vaccine cell-based stem cells to deliver the vaccine.
– Get survival over 20 years, early diagnosis, optimizing treatment,
DISCUSSION on the Future of immunotherapy
| #startup#biotech
#CancerTherapy #pharmanews |
@SachsAssociates@pharma_BI
@BiotechNews |
2012pharmaceutical
sjwilliamspa